A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer
M Altinbas, HS Coskun, O Er, M Ozkan… - … of thrombosis and …, 2004 - Wiley Online Library
Background Small cell lung cancer (SCLC) is a chemotherapy‐responsive tumor type but
most patients ultimately experience disease progression. SCLC is associated with …
most patients ultimately experience disease progression. SCLC is associated with …
[图书][B] Thrombosis and cancer
G Lugassy, A Falanga, AK Kakkar, FR Rickles - 2004 - books.google.com
This text provides comprehensive and timely coverage of the current knowledge of cancer-
associated thrombosis, its pathogenesis, clinical features, prevention, and therapy. It …
associated thrombosis, its pathogenesis, clinical features, prevention, and therapy. It …
The fibrinolytic system in cancer
G Lugassy, A Klepfish - Thrombosis and Cancer, 2004 - taylorfrancis.com
The fibrinolytic system in cancer Page 1 5 The fibrinolytic system in cancer Gilles Lugassy and
Abraham Klepfish The fibrinolytic (plasminogen–plasmin proteolytic enzyme) system is …
Abraham Klepfish The fibrinolytic (plasminogen–plasmin proteolytic enzyme) system is …
Antimalignant properties of antithrombotic agents
CPW Klerk, SM Smorenburg… - Thrombosis and cancer …, 2004 - books.google.com
Because of the high risk of thrombosis, cancer patients often receive anticoagulants as
prophylaxis or treatment. It has been suggested that antithrombotic agents influence cancer …
prophylaxis or treatment. It has been suggested that antithrombotic agents influence cancer …
Vitamin K antagonists (VKA) Experimental studies
G Lugassy, A Falanga, AK Kakkar… - Thrombosis and …, 2004 - api.taylorfrancis.com
In animal experiments, positive effects have been reported with thrombolytic agents. Here
the emphasis has been on metastasis, and not so much on effects on the primary tumor …
the emphasis has been on metastasis, and not so much on effects on the primary tumor …